Boehringer Ingelheim needs new revenue streams. Good thing it has launched four new products over the past year--and it's eyeing two of them as potential leaders in their classes.
New oral anticoagulants--such as Johnson & Johnson's Xarelto and Boehringer Ingelheim's Pradaxa--have been in fierce competition with one another for awhile now. But they still have a ways to go to displace the old-guard therapy warfarin--and one GlobalData analyst thinks she knows why.
The European Medicines Agency is moving toward approving a trio of novel medicines from Roche, Boehringer Ingelheim and Gilead Sciences, handing down positive recommendations for each.
Boehringer Ingelheim has finalized the crowdsourced chronic obstructive pulmonary disease (COPD) R&D team it has spent the past 9 months putting together with BioMed X. The partners have tapped the University of Stuttgart's Renata Jurkowska to lead the initiative, which is an attempt by Boehringer to draw on expertise outside of its walls to better understand the epigenetics of COPD.
The only inhaler that administers a slow-moving mist to help respiratory patients inhale the medication is now FDA-approved for the long-term maintenance treatment of asthma, in addition to its previous indication to treat COPD.
Top-line data on Eli Lilly and Boehringer Ingelheim's SGLT2 med, Jardiance, is out, showing the drug cut the combined risk of heart attack, stroke and death from cardiovascular causes by 14% in high-risk Type 2 diabetes patients. But what does it mean for the ultracompetitive diabetes landscape?
Since Eli Lilly and Boehringer Ingelheim announced that their SGLT2 med, Jardiance, had become the first to show it could lower the risk of major cardiovascular events, the question on the minds of industry watchers has been "How much?"
Late last month, Eli Lilly and Boehringer Ingelheim said their SGLT2 med, Jardiance, became the first diabetes med to show it could actually lower the risk of heart attack, stroke and death from cardiovascular causes. But even with that potentially hefty benefit, payers aren't getting ahead of themselves.
Boehringer Ingelheim and Roche's meds for idiopathic pulmonary fibrosis may have won FDA approval on the same day, but in Europe, BI's contender, Ofev, has been playing catch-up since snagging its regulatory green-light. On Friday, though, it got a boost from British cost watchdogs could help it out in that department.
LONDON-- Boehringer Ingelheim's Pradaxa currently trails Johnson & Johnson and Bayer med Xarelto in the market for new-age anticoagulants, but the German drugmaker is hoping a nod for its antidote candidate will help turn the tide in its favor.